Review: Short-acting insulin analogues reduce glycosylated hemoglobin more than regular human insulin but only in adults with type 1 diabetes

摘要

ACP Journal Club. 2005 May-Jun;142:63.nSiebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2004;(4):CD003287. [PubMed ID: 15495047] nnQuestionnnIn patients with diabetes, is a short-acting insulin analogue more effective than regular human insulin?nnMethodsnnData sources: 3 databases, references of studies and reviews, abstracts of major diabetology meetings, hand-searches of diabetes journals, the International Register of Clinical Trials Registers, the register of Current Science, 3 main pharmaceutical companies producing short-acting insulin analogues (Aventis, Eli Lilly, and Novo Nordisk), experts and approval agencies, and bibliographies of standard textbooks.